{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:19Z","timestamp":1792521439323,"version":"4.5.0"},"reference-count":157,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science, Technological Development and Innovation, Republic of Serbia","award":["200110"],"award-info":[{"award-number":["200110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The hepatitis B surface antigen (HBsAg) is a multifunctional glycoprotein composed of large (LHB), middle (MHB), and small (SHB) subunits. HBsAg isoforms have numerous biological functions during HBV infection\u2014from initial and specific viral attachment to the hepatocytes to initiating chronic infection with their immunomodulatory properties. The genetic variability of HBsAg isoforms may play a role in several HBV-related liver phases and clinical manifestations, from occult hepatitis and viral reactivation upon immunosuppression to fulminant hepatitis and hepatocellular carcinoma (HCC). Their immunogenic properties make them a major target for developing HBV vaccines, and in recent years they have been recognised as valuable targets for new therapeutic approaches. Initial research has already shown promising results in utilising HBsAg isoforms instead of quantitative HBsAg for correctly evaluating chronic infection phases and predicting functional cures. The ratio between surface components was shown to indicate specific outcomes of HBV and HDV infections. Thus, besides traditional HBsAg detection and quantitation, HBsAg isoform quantitation can become a useful non-invasive biomarker for assessing chronically infected patients. This review summarises the current knowledge of HBsAg isoforms, their potential usefulness and aspects deserving further research.<\/jats:p>","DOI":"10.3390\/pathogens13010046","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:31:50Z","timestamp":1704281510000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-1378","authenticated-orcid":false,"given":"Ivana","family":"Lazarevic","sequence":"first","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-096X","authenticated-orcid":false,"given":"Ana","family":"Banko","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-8701","authenticated-orcid":false,"given":"Danijela","family":"Miljanovic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cupic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"ref_2","unstructured":"World Health Organization (2022). Hepatitis B, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_5","first-page":"1425","article-title":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0039-3401031","article-title":"Role of Biomarkers in Guiding Cure of Viral Hepatitis B","volume":"40","author":"Buti","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bpg.2017.04.013","article-title":"The virological aspects of hepatitis B","volume":"31","author":"Valaydon","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virusres.2007.02.021","article-title":"Hepatitis B virus genetic variability and evolution","volume":"127","author":"Kay","year":"2007","journal-title":"Virus Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.clinre.2023.102180","article-title":"A review of epidemiology and clinical relevance of Hepatitis B virus genotypes and subgenotypes","volume":"47","author":"Chen","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_11","first-page":"231","article-title":"Genomic heterogeneity of hepatitis B virus in a 54-year old woman who contracted the infection through materno- fetal transmission","volume":"57","author":"Okamoto","year":"1987","journal-title":"Jpn. J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jare.2019.03.009","article-title":"A review on hepatitis D: From virology to new therapies","volume":"17","author":"Mentha","year":"2019","journal-title":"J. Adv. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Inoue, J., Sato, K., Ninomiya, M., and Masamune, A. (2021). Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses, 13.","DOI":"10.3390\/v13061124"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/jvi.52.2.396-402.1984","article-title":"Large surface proteins of hepatitis B virus containing the pre-S sequence","volume":"52","author":"Heermann","year":"1984","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3748\/wjg.v24.i14.1507","article-title":"Hepatitis B virus pre-S\/S variants in liver diseases","volume":"24","author":"Chen","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dobrica, M.O., Lazar, C., and Branza-Nichita, N. (2020). N-Glycosylation and N-Glycan Processing in HBV Biology and Pathogenesis. Cells, 9.","DOI":"10.3390\/cells9061404"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, F. (2018). Post-translational modification control of HBV biological processes. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02661"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/jvi.61.5.1672-1677.1987","article-title":"The preS1 protein of hepatitis B virus is acylated at its aminoterminus with myristic acid","volume":"61","author":"Persing","year":"1987","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1099\/vir.0.79932-0","article-title":"Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus","volume":"85","author":"Schmitt","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: Pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2201","DOI":"10.1002\/rmv.2201","article-title":"Hepatitis B virus pre-S region: Clinical implications and applications","volume":"31","author":"Sun","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/j.1460-2075.1995.tb06998.x","article-title":"Novel transmembrane topology of the hepatitis B virus envelope proteins","volume":"14","author":"Prange","year":"1995","journal-title":"EMBO J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16178","DOI":"10.1038\/s41598-019-52824-z","article-title":"Direct interaction between the hepatitis B virus core and envelope proteins analyzed in a cellular context","volume":"9","author":"Pastor","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00272-18","DOI":"10.1128\/JVI.00272-18","article-title":"Common and Distinct Capsid and Surface Protein Requirements for Secretion of Complete and Genome-Free Hepatitis B Virions","volume":"92","author":"Ning","year":"2018","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.chom.2016.05.013","article-title":"A Slow Maturation Process Renders Hepatitis B Virus Infectious","volume":"20","author":"Seitz","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/JVI.02528-09","article-title":"The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly","volume":"84","author":"Ni","year":"2010","journal-title":"J. Virol."},{"key":"ref_28","first-page":"122","article-title":"Role of glycosaminoglycans for binding and infection of hepatitis B virus","volume":"10","author":"Leistner","year":"2008","journal-title":"Cell Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","article-title":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","volume":"30","author":"Corti","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1126\/science.2408336","article-title":"Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen","volume":"228","author":"Milich","year":"1985","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"691766","DOI":"10.3389\/fimmu.2021.691766","article-title":"The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection","volume":"7","author":"Vaillant","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jmb.2009.04.059","article-title":"Structure of hepatitis B surface antigen from subviral tubes determined by electron cryomicroscopy","volume":"390","author":"Short","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Stieler, J.T., and Prange, R. (2014). Involvement of ESCRT-II in hepatitis B virus morphogenesis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091279"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1073\/pnas.0704000104","article-title":"Involvement of host cellular multivesicular body functions in hepatitis B virus budding","volume":"104","author":"Watanabe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1128\/JVI.03109-15","article-title":"Subviral hepatitis B virus filaments, like infectious viral particles, are released via multivesicular bodies","volume":"90","author":"Jiang","year":"2016","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2017.05.017","article-title":"Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro","volume":"509","author":"Rydell","year":"2017","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1084\/jem.178.5.1541","article-title":"Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis","volume":"178","author":"Ando","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11916","DOI":"10.1128\/JVI.05373-11","article-title":"Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesisof the plus-strand DNA in hepatitis B virus","volume":"85","author":"Lentz","year":"2011","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1128\/jvi.68.9.5706-5713.1994","article-title":"Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes","volume":"68","author":"Lenhoff","year":"1994","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.510290236","article-title":"Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus","volume":"29","author":"Lenhoff","year":"1999","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4254\/wjh.v7.i27.2729","article-title":"Clinical significance of hepatitis B surface antigen mutants","volume":"7","author":"Coppola","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lazarevic, I., Banko, A., Miljanovic, D., and Cupic, M. (2019). Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses, 11.","DOI":"10.3390\/v11090778"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(88)90541-7","article-title":"Hepatitis B variant in Europe","volume":"2","author":"Zanetti","year":"1988","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0140-6736(90)91874-A","article-title":"Vaccine-induced escape mutant of hepatitis B virus","volume":"336","author":"Carman","year":"1990","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jmv.20605","article-title":"Hepatitis B virus genetic diversity","volume":"78","author":"Echevarria","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Saitta, C., Pollicino, T., and Raimondo, G. (2022). Occult Hepatitis B Virus Infection: An Update. Viruses, 14.","DOI":"10.3390\/v14071504"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MOH.0b013e32834bac10","article-title":"Challenges in hepatitis B detection among blood donors","volume":"18","author":"Allain","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1537-2995.2008.01701.x","article-title":"Hepatitis B virus infection and transfusion medicine: Science and the occult","volume":"48","author":"Hollinger","year":"2008","journal-title":"Transfusion"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2011.10.022","article-title":"Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection","volume":"93","author":"Svicher","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2012.05.009","article-title":"Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors","volume":"57","author":"Huang","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1211980","DOI":"10.3389\/fimmu.2023.1211980","article-title":"Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.25592","article-title":"Impact of hepatitis B virus (HBV) preS\/S genomic variability on HBV surface antigen and HBV DNA serum levels","volume":"56","author":"Pollicino","year":"2012","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Guo, Y., Lan, Y., Jing, Y., Cai, B., Gong, H., Zhang, Y., and Duan, Y. (2022). The Investigation of HBV Pre-S\/S Gene Mutations in Occult HBV Infected Blood Donors with anti-HBs Positive. Can. J. Infect. Dis. Med. Microbiol., 2022.","DOI":"10.1155\/2022\/1874435"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105448","DOI":"10.1016\/j.antiviral.2022.105448","article-title":"Naturally occurring pre-S mutations promote occult HBV infection by affecting pre-S2\/S promoter activity","volume":"208","author":"Sun","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.20703","article-title":"AASLD position paper: The management of acute liver failure","volume":"41","author":"Polson","year":"2005","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11908-019-0682-9","article-title":"Management of Fulminant Hepatitis B","volume":"21","author":"Ichai","year":"2019","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/HEP.0000000000000335","article-title":"HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice","volume":"78","author":"Uchida","year":"2023","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1231204","DOI":"10.1155\/2017\/1231204","article-title":"Novel Genetic Variants of Hepatitis B Virus in Fulminant Hepatitis","volume":"2017","author":"Chook","year":"2017","journal-title":"J. Pathog."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3748\/wjg.v24.i31.3488","article-title":"Hepatitis B virus infection: Defective surface antigen expression and pathogenesis","volume":"24","author":"Wu","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.510260235","article-title":"Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis","volume":"26","author":"Pollicino","year":"1997","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0168-8278(97)80239-5","article-title":"Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis","volume":"26","author":"Sterneck","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/jhep.2001.26516","article-title":"A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis","volume":"34","author":"Kalinina","year":"2001","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/fvl-2020-0011","article-title":"Biological features of hepatitis B virus strains associated with fulminant hepatitis","volume":"15","author":"Lazarevic","year":"2020","journal-title":"Future Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(92)90182-X","article-title":"High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis","volume":"102","author":"Lau","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0016-5085(93)90032-8","article-title":"Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis","volume":"105","author":"Mason","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/hep.1840360605","article-title":"Revisiting the cytopathic effect of hepatitis B virus infection","volume":"36","author":"Bruss","year":"2002","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12072-018-9858-x","article-title":"The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection","volume":"12","author":"Li","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e29477","DOI":"10.5812\/hepatmon.29477v2","article-title":"Genomic diversity of hepatitis B virus infection associated with fulminant hepatitis B development","volume":"15","author":"Mina","year":"2015","journal-title":"Hepat. Mon."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Anastasiou, O.E., Theissen, M., Verheyen, J., Bleekmann, B., Wedemeyer, H., Widera, M., and Ciesek, S. (2019). Clinical and virological aspects of HBV reactivation: A focus on acute liver failure. Viruses, 11.","DOI":"10.3390\/v11090863"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e28436","DOI":"10.1002\/jmv.28436","article-title":"The HBV web: An insight into molecular interactomes between the hepatitis B virus and its host en route to hepatocellular carcinoma","volume":"95","author":"Kar","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/djp180","article-title":"Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysis","volume":"101","author":"Liu","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1349-7006.2006.00235.x","article-title":"Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis","volume":"97","author":"Wang","year":"2006","journal-title":"Cancer Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1478-3231.2012.02826.x","article-title":"Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma","volume":"32","author":"Kao","year":"2012","journal-title":"Liver Int."},{"key":"ref_78","first-page":"1","article-title":"Hepatitis B virus large surface protein: Function and fame","volume":"4","author":"Churin","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"20312","DOI":"10.18632\/oncotarget.7950","article-title":"Exogenous hepatitis B virus envelope proteins induce endoplasmicreticulum stress: Involvement of cannabinoid axis in liver cancer cells","volume":"7","author":"Montalbano","year":"2016","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1440-1746.2008.05348.x","article-title":"Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection","volume":"23","author":"Su","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Choi, Y.M., Lee, S.Y., and Kim, B.J. (2019). Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030597"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lin, Y.T., Jeng, L.B., Chan, W.L., Su, I.J., and Teng, C.F. (2021). Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses, 13.","DOI":"10.3390\/v13050862"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/hep.22889","article-title":"Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis","volume":"49","author":"Yang","year":"2009","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"46384","DOI":"10.1074\/jbc.M403568200","article-title":"Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase","volume":"279","author":"Hung","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.20615","article-title":"Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes","volume":"41","author":"Wang","year":"2005","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-07-0098","article-title":"Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27kip1 through c-jun activation domain-binding protein 1","volume":"5","author":"Hsieh","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Hung, J.H., Teng, Y.N., Wang, L.H.C., Su, I.J., Wang, C.C., Huang, W., Lee, K.H., Lu, K.Y., and Wang, L.H. (2011). Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028977"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/emboj\/21.4.525","article-title":"The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1\/Erk2 signaling in transgenic mice","volume":"21","author":"Hildt","year":"2002","journal-title":"EMBO J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/gut.2008.174029","article-title":"Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT","volume":"58","author":"Luan","year":"2009","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/135965350801300701","article-title":"The oncogenic potential of hepatitis B virus rtA181T\/ surface truncation mutant","volume":"13","author":"Lai","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis B","volume":"2","author":"Mak","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jviromet.2015.11.016","article-title":"The Lumipulse G HBsAg- Quant assay for screening and quantification of the hepatitis B surface antigen","volume":"228","author":"Yang","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","article-title":"An ultra-sensitive Abbott ARCHITECT\u00ae assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"105","author":"Lou","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/gutjnl-2018-317385","article-title":"Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus","volume":"68","author":"Yang","year":"2019","journal-title":"Gut"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Pollicino, T., and Caminiti, G. (2021). HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13.","DOI":"10.3390\/v13030368"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Vachon, A., and Osiowy, C. (2021). Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses, 13.","DOI":"10.3390\/v13060951"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lazarevic, I., Banko, A., Miljanovic, D., and Cupic, M. (2023). Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses, 15.","DOI":"10.3390\/v15020373"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0042-6822(82)90275-6","article-title":"Variable protein composition of hepatitis B surface antigen from different donors","volume":"123","author":"Stibbe","year":"1982","journal-title":"Virology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/0016-5085(87)90617-2","article-title":"Pre-S encoded surface proteins in relation to the major viral surface antigen in acute hepatitis B virus infection","volume":"92","author":"Gerken","year":"1987","journal-title":"Gastroenterology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00190150","article-title":"Assay of preS epitopes and preS1 antibody in hepatitis B virus carriers and immune persons","volume":"179","author":"Deepen","year":"1990","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/infdis\/jiy119","article-title":"Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles from HBV e Antigen-Negative Patients","volume":"218","author":"Peiffer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2016.12.003","article-title":"Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes","volume":"502","author":"Hassemer","year":"2017","journal-title":"Virology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1128\/JVI.01293-16","article-title":"In vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes","volume":"90","author":"Sozzi","year":"2016","journal-title":"J. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.14298","article-title":"Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a","volume":"40","author":"Rinker","year":"2020","journal-title":"Liver Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2020.08.039","article-title":"Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B","volume":"74","author":"Pfefferkorn","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100842","DOI":"10.1016\/j.jhepr.2023.100842","article-title":"HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers","volume":"5","author":"Roade","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2018.02.015","article-title":"Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients","volume":"481","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e0027","DOI":"10.1097\/HC9.0000000000000027","article-title":"Characterization of HBV surface antigen isoforms in the natural history and treatment of HBV infection","volume":"7","author":"Rodgers","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/liv.12642","article-title":"HBV preS2 transactivates FOXP3 expression in malignant hepatocytes","volume":"35","author":"Zhang","year":"2015","journal-title":"Liver Int."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Brancaccio, G., Salpini, R., Piermatteo, L., Surdo, M., Fini, V., Colagrossi, L., Cantone, M., Battisti, A., Oda, Y., and Di Carlo, D. (2021). An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040752"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/jvh.13557","article-title":"Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients","volume":"28","author":"Nishida","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Tsai, H.W., Lee, Y.P., Yen, C.J., Cheng, K.H., Huang, C.J., and Huang, W. (2022). The Serum Hepatitis B Virus Large Surface Protein as High-Risk Recurrence Biomarker for Hepatoma after Curative Surgery. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105376"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Murata, A., Angata, K., Sogabe, M., Sato, S., Ichida, T., Narimatsu, H., and Genda, T. (2022). Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02352-4"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jvh.13869","article-title":"Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients","volume":"30","author":"Okumura","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000441-197509000-00021","article-title":"Attempt to prevent hepatitis by using specific anti-HBs immunoglobulin","volume":"270","author":"Delons","year":"1975","journal-title":"Am. J. Med. Sci."},{"key":"ref_118","unstructured":"Blumberg, B.S., and Millman, I. (1972). Vaccine against Viral Hepatitis and Process. (US 3636191A), U.S. Patent."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0264-410X(88)90183-1","article-title":"Anti-preS2 antibodies in natural hepatitis B virus infection and after immunization","volume":"6","author":"Coursaget","year":"1988","journal-title":"Vaccine"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.1986.03380070075022","article-title":"The safety of the hepatitis B vaccine: Inactivation of the AIDS virus during routine vaccine manufacture","volume":"256","author":"Francis","year":"1986","journal-title":"JAMA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-4453(86)92563-6","article-title":"Production and immunological analysis of recombinant hepatitis B vaccine","volume":"13","author":"Emini","year":"1986","journal-title":"J. Infect."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt0587-479","article-title":"High-level expression and effcient assembly of hepatitis B surface antigen in the methylotrophic yeast, Pichia pastoris","volume":"5","author":"Cregg","year":"1987","journal-title":"Nat. Biotechnol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1574-6968.1998.tb13171.x","article-title":"Fine structure of hepatitis B virus surface antigen produced by recombinant yeast: Comparison with HBsAg of human origin","volume":"165","author":"Yamaguchi","year":"1998","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00430-014-0373-y","article-title":"Prophylactic vaccination against hepatitis B: Achievements, challenges and perspectives","volume":"204","author":"Gerlich","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ho, J.K., Jeevan-Raj, B., and Netter, H.J. (2020). Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses, 12.","DOI":"10.3390\/v12020126"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0264-410X(88)90173-9","article-title":"Recombinant versus plasma-derived hepatitis B vaccines: Issues of safety, immunogenicity and cost-effectiveness","volume":"6","author":"Stephenne","year":"1988","journal-title":"Vaccine"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1093\/hmg\/ddt586","article-title":"A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations","volume":"23","author":"Pan","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1038\/srep27251","article-title":"Factors influencing immunologic response to hepatitis B vaccine in adults","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3748\/wjg.v28.i31.4249","article-title":"Insights into induction of the immune response by the hepatitis B vaccine","volume":"28","author":"Flichman","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitits B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14760584.2021.1908133","article-title":"CpG-Adjuvated hepatitis B Vaccine (HEPLISAV-B\u00ae) Update","volume":"20","author":"Lee","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0264-410X(89)90235-1","article-title":"Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective","volume":"7","author":"Neurath","year":"1989","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0167-5699(88)91239-X","article-title":"T- and B-cell recognition of hepatitis B viral antigens","volume":"9","author":"Milich","year":"1988","journal-title":"Immunol. Today"},{"key":"ref_137","first-page":"143","article-title":"Immunogenicity of Sci-Bvac (a third-generation hepatitis B vaccine) in HIV-positive adults","volume":"19","author":"Alon","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0264-410X(92)90067-T","article-title":"Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine","volume":"10","author":"Coursaget","year":"1992","journal-title":"Vaccine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/jhep.2001.26167","article-title":"Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine","volume":"34","author":"Young","year":"2001","journal-title":"Hepatology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0264-410X(90)90044-M","article-title":"Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine)","volume":"8","author":"Fujisawa","year":"1990","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/jhep.2001.27564","article-title":"Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines","volume":"34","author":"Zuckerman","year":"2001","journal-title":"Hepatology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S1473-3099(20)30780-5","article-title":"Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): A randomised, double-blind, phase 3 trial","volume":"21","author":"Vesikari","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e2128652","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: A phase 3 Randomized Clinical Trial","volume":"4","author":"Vesikari","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nchembio.1403","article-title":"Adaptive immune activation: Glycosylation does matter","volume":"9","author":"Wolfert","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Degasperi, E., Anolli, M.P., and Lampertico, P. (2022). Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. Viruses, 14.","DOI":"10.3390\/v14112404"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000360948","article-title":"Inhibitors of hepatitis B virus attachment and entry","volume":"57","author":"Lempp","year":"2014","journal-title":"Intervirology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jvh.13081","article-title":"New treatment options for delta virus: Is a cure in sight?","volume":"26","author":"Yurdaydin","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jvh.13490","article-title":"Clinical effects of NTCP-inhibitor myrcludex B","volume":"28","author":"Cheng","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Al-Mahtab, M., Bazinet, M., and Vaillant, A. (2016). Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156667"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Na\u00efve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): A non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep4.1951","article-title":"HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV\/HDV infection","volume":"6","author":"Bazinet","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.coviro.2022.101205","article-title":"Advances in human monoclonal antibody therapy for HBV infection","volume":"53","author":"Beretta","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2023.07.003","article-title":"Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice","volume":"79","author":"Lempp","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.3748\/wjg.v21.i24.7400","article-title":"Applications of human hepatitis B virus preS domain in bio- and nanotechnology","volume":"21","author":"Toita","year":"2015","journal-title":"World J. Gastroenterol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:39:20Z","timestamp":1760103560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["pathogens13010046"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13010046","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]}}}